Figures & data
Table 1 Demographic and baseline characteristics of COPD cohort by the GOLD 17 group
Figure 1 Patient classification by the GOLD group.
Figure 2 Treatments prescribed within 3 months of study start by the GOLD 2017 group.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; LAMA; long-acting muscarinic antagonist; SABA, short-acting β2 agonists; SAMA, short-acting muscarinic antagonist.
Figure 3 Comparison of estimated treatment costs compared to GOLD 2017 recommendations.
